CEOs got their deal-making mojo back in 2014, emboldened by a clearer outlook for their businesses to take M&As to their highest level since 2007.» Read More
CNBC's Catherine Boyle reports on Pfizer's charm offensive as its CEO Ian Read flew in to London for a round of meetings with politicians and investors.
Don't blame Apple for its debt offering or Pfizer for going overseas—blame those who write the US tax code, says NYU Stern Professor Aswath Damodaran.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Sue Noffke, U.K. equities fund manager at Schroders, says Pfizer wants AstraZeneca's oncology drugs pipeline which looks promising.
Can there be a clearer illustration of the chasm between French and UK attitudes to business than this week's M&A headlines, writes Steve Sedgwick.
The euro traded at multi-week highs against the yen early on Tuesday and held firm against the dollar after a strong performance overnight.
Argus Research's John Eade weighs in on growing M&A in the pharma space.
Pfizer's $100 billion offer to acquire British rival AstraZeneca is an effort to achieve an "efficient" tax structure, the company said.
Stocks rose on Monday, bouncing back after the prior session's drop, amid increased deal activity.
CNBC's Eamon Javers takes a close look at Pfizer's $100 billion bid for AstraZeneca. The deal would elevate Pfizer's cancer drug pipeline while giving them enormous tax savings.
Damien Conover, Morningstar analyst, thinks the Pfizer bid for AstraZeneca will go through. CNBC's Meg Tirrell provides perspective.
The euro rose to a two-week high against the dollar on Monday, supported by expectations inflation in the euro zone will tick up.
CNBC's Eamon Javers takes a close look at Pfizer's $100 billion bid for AstraZeneca.
With stocks buoyed by a flurry of dealmaking on Monday, Blackstone CEO Steve Schwarzman says absolute valuations are "on the higher side."
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Investors are unwinding leverage somewhat, yet most remain committed to the stock market amid talk of a new rotation.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.
Some of the names on the move ahead of the open.
Bayer CEO Marijn Dekkers told CNBC he did not feel a need to make acquisitions on Monday.